source
- Merck says 2027 will focus on pipeline and new product launches despite recent trial winsMerck's chief financial officer said the company views 2027 as another year of investment, emphasizing its expanding pipeline and upcoming product launches rather than short‑term margin growth. Th…
- Moderna and Merck vaccine plus Keytruda cuts melanoma relapse risk by 42% in late-stage trialA late-stage adjuvant study of Moderna’s experimental melanoma vaccine, intismeran autogene, combined with Merck’s Keytruda showed a 42% reduction in the risk of relapse or death compared with Keyt…